Linking dose to disease relevant biomarkers to clinical benefit
10 Sept 2026
Target Discovery
- What is the relationship between human dose, target occupancy, and duration of target engagement?
- How does target engagement translate into modulation of disease-relevant biomarkers?
- How does disease stage influence dose–biomarker–response relationships?
- How can early intervention be optimized to alter disease progression?
